ismagilov
Telomir Pharmaceuticals (TELO) has filed for a proposed $14M initial public offering.
The biotech company didn’t set any terms in its SEC filing, but indicated in a filing fee schedule that it was seeking to raise around $14M. Kingswood Investments is serving as lead bookrunner.
Telomir hopes to list its shares on Nasdaq under the symbol TELO.
Based in Maryland, Telomir’s lead drug candidate, TELOMIR-1, is an orally administered IL-17 inhibitor. The company plans to develop the drug, which is in the preclinical stage, as a potential treatment for post-chemotherapy recovery and age-related inflammatory conditions such as osteoarthritis.